-
An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trialLopes RD, Vora AN, Liaw D et al. -
Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials JACC Scientific Expert PanelB Ibanez, AH Aletras, AE Arai et al.
-
Considerations for Single-Measurement Risk-Stratification Strategies for Myocardial Infarction Using Cardiac Troponin AssaysPV Caposino, MV Kondratovich.
-
Treating Multivessel Coronary Artery Disease in ST-Segment Elevation Myocardial Infarction: Why, How, and When?Berry C, Collison D, Mangion K.
-
Chronic Kidney Disease and Coronary Artery DiseaseMJ Sarnak, K Amann, S Bangalore et al.
-
Aggressive lipid-lowering therapy after percutaneous coronary intervention – for whom and how?Z-V Lee.
-
Positive remodelling of coronary arteries on computed tomography coronary angiogram: an observational studyMK Hu, MS Yuan, S James et al.
-
Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial葛震、阚静、高晓飞、陈绍良、Gregg W. Stone
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
